Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis
Top Cited Papers
- 5 September 2013
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 75 (1), 43-49
- https://doi.org/10.1002/ana.24018
Abstract
Objective To evaluate the extent to which treatment effect on brain atrophy is able to mediate, at the trial level, the treatment effect on disability progression in relapsing–remitting multiple sclerosis (RRMS). Methods We collected all published randomized clinical trials in RRMS lasting at least 2 years and including as endpoints disability progression (defined as 6 or 3 months confirmed 1‐point increase on the Expanded Disability Status Scale), active magnetic resonance imaging (MRI) lesions (defined as new/enlarging T2 lesions), and brain atrophy (defined as change in brain volume between month 24 and month 6–12). Treatment effects were expressed as relative reductions. A linear regression, weighted for trial size and duration, was used to assess the relationship between the treatment effects on MRI markers and on disability progression. Results Thirteen trials including >13,500 RRMS patients were included in the meta‐analysis. Treatment effects on disability progression were correlated with treatment effects both on brain atrophy (R2 = 0.48, p = 0.001) and on active MRI lesions (R2 = 0.61, p < 0.001). When the effects on both MRI endpoints were included in a multivariate model, the correlation was higher (R2 = 0.75, p < 0.001), and both variables were retained as independently related to the treatment effect on disability progression. Interpretation In RRMS, the treatment effect on brain atrophy is correlated with the effect on disability progression over 2 years. This effect is independent of the effect of active MRI lesions on disability; the 2 MRI measures predict the treatment effect on disability more closely when used in combination. ANN NEUROL 2014;75:43–49This publication has 26 references indexed in Scilit:
- MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trialsThe Lancet Neurology, 2013
- Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosisMultiple Sclerosis Journal, 2010
- Surrogate endpoints for EDSS worsening in multiple sclerosisNeurology, 2010
- Imaging outcomes for neuroprotection and repair in multiple sclerosis trialsNature Reviews Neurology, 2009
- Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta‐analytic approachAnnals of Neurology, 2009
- Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosisNeurology, 2008
- Association of Neocortical Volume Changes With Cognitive Deterioration in Relapsing-Remitting Multiple SclerosisArchives of Neurology, 2007
- Brain atrophy and lesion load in a large population of patients with multiple sclerosisNeurology, 2005
- MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1bNeurology, 2003
- MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patientsNeurology, 2002